Wire · opportunities
Abbisko's lavengratinib achieves 100% responder rate in early achondroplasia trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
Abbisko Therapeutics' oral FGFR2/3 inhibitor lavengratinib achieved a 100% responder rate in a Phase II trial for children with achondroplasia, showing a mean annual height velocity increase of +2.4 cm/year and no serious adverse events at the lowest dose tested. The drug offers a mechanistic and administration route differentiation from existing therapies, with further data expected by end of 2026.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a growing oral alternative to injected achondroplasia drugs that may widen patient access and improve compliance. Assess your positioning against oral FGFR inhibitors like lavengratinib and BridgeBio’s infigratinib as competition tightens in this rare bone growth disorder.
◆ Coverage
1 source · 21 Sep 2026
◆ Related on Wire
◆ Topics